* Lunit to present five posters at ESMO 2022 featuring the company's AI-biomarker platform * St...
* Lunit's AI solution for mammography received a class 2 medical device license from the Taiwan F...
* Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-yea...
* Recent clinical trial on combination immunotherapy for nasopharyngeal cancer provides evidence ...
SEOUL, South Korea, July 21, 2022 /PRNewswire/ -- Lunit, a global provider of AI-powered cancer sol...
* Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000 * To be listed ...
* Lunit and Cathay Life Insurance signed a license agreement to officially adopt Lunit's AI solut...
* Lunit and FujiFilm Thailand to supply Lunit INSIGHT CXR and Lunit INSIGHT MMG to one of SEA's l...
* First Korean healthcare company to obtain "AA-AA" ratings in technology assessment for its FDA-...
* Lunit to showcase 7 poster presentations and 4 online publications, the company's largest publi...
* Study findings show that Lunit's AI-powered PD-L1 TPS analyzer minimizes interpretation discrep...
* 7 poster presentations and 4 online publications, including research on AI biomarkers, have bee...
* Lunit gets greenlight to accelerate listing on the KOSDAQ market * First Korean healthcare com...
* Lunit to present two abstracts about its AI-biomarker for immunotherapy, Lunit SCOPE IO * Lun...
* Lunit's latest study provides evidence for Lunit SCOPE IO's ability to predict immunotherapy re...
SEOUL, South Korea, Jan. 18, 2022 /PRNewswire/ -- Lunit today announced a Reference Site Agreement ...
* Lunit meets MDSAP requirements as a global standard medical AI software manufacturer * QMS au...
SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- CB Insights
- New investors include US life science investors HealthQuest Capital, Casdin Capital, and American...
SEOUL, South Korea, Nov. 18, 2021 /PRNewswire/ -- Lunit, a leading medical AI provider, today annou...
